PRINT THIS PAGE

For the life sciences industry, small may just be the biggest thing yet

Rapid progress and plenty of hype have made nanotechnology the next big thing. In fact, nano has now firmly replaced dot-com as the technological buzzword of our time. In fact, some argue that the buzz is running too far ahead of nanotechnology's ability to deliver. Mikayel Nazoyan of PricewaterhouseCoopers looks at the importance of this ever growing sector.

Nanotechnology is slowly finding a place in biomedicine as it moves from research into the experimental stages. And a growing number of investors are taking notice. The US government, for one, is pumping nearly half a billion into the field.

You need Adobe Acrobat to read this document. If you do not have it, you can download it free from www.adobe.com/products/acrobat/readstep.html

PricewaterhouseCoopers provides thought leadership on issues affecting life sciences companies. They publish authoritative materials focused on topics such as healthcare reform, the public equity market, and alternative funding sources such as venture and off-balance sheet R&D financing, compensation and organisational trends, strategic partnering, and valuation in-process R&D.www.pwcglobal.com